Many have declared drugs like Ozempic could “end obesity” by reducing the appetite and waistlines of thousands and thousands of individuals all over the world.
When we glance past the hype, this isn’t just unfaithful – it might probably even be harmful. The give attention to weight, versus health, is a feature of eating regimen culture. This frames the pursuit of thinness as more vital than other points of physical and cultural wellbeing.
The Ozempic buzz isn’t just rooted in health and medicine but plays into ideas of fat stigma and fat phobia. This can perpetuate fears of fatness and fat people, and the behaviours that harm individuals who live in larger bodies.
Not the primary ‘miracle’ weight-loss drug
This isn’t the primary time now we have heard that weight-loss drugs will change the world. Ozempic and its family of GLP-1-mimicking drugs are the newest in a protracted line of weight reduction drugs. Each looked promising on the time. But none have lived as much as the hype in the long run. Some have even been withdrawn from sale because of severe unwanted side effects.
Science does improve incrementallybut eating regimen culture also keeps us on a cycle of hope for the subsequent miracle cure. So drugs like Ozempic won’t deliver the outcomes individuals expect, continuing the cycle of hope and shame.
Ozempic doesn’t work the identical for everybody
When we talk concerning the results of studies using Ozempic, we regularly give attention to the typical (also often known as the mean) results or the utmost (or peak) results. So, studies might show those using the drug lost a mean of 10.9% of their body weight, but some lost greater than 20% and others lower than 5%
What we don’t discuss as much is that responses are variable. Some persons are “non-responders”. This means not everyone loses as much weight as the typical, and a few don’t shed weight in any respect. For some people, the side-effects will outweigh the advantages.
When persons are on drugs like Ozempic, their blood sugar is best controlled by enhancing the discharge of insulin and reducing the degrees of one other hormone called glucagon.
But there is larger variability in the quantity of weight lost than the variability in blood sugar control. It isn’t clear why, but is probably going because of differences in genetics and lifestyles, and weight being more complex to manage.
Treatment must be ongoing. What will this mean?
When weight-loss drugs do work, they’re only effective while they’re being taken. This implies that to maintain the load off people have to keep taking them long run. One study found a mean weight reduction of greater than 17% after a 12 months on Ozempic became a mean net weight reduction of 5.6% greater than two years after stopping treatment.
Manop Boonpeng/Shutterstock
Short-term unwanted side effects of medication like Ozempic include dizziness, nausea, vomiting and other gastrointestinal upsets. But because these are latest drugs, we simply don’t have data to inform us if unwanted side effects will increase as people take them for longer periods.
Nor can we know if effectiveness will likely be reduced in the long run. This is named drug tolerance and is documented for other long-term treatments akin to antidepressants and chemotherapies.
Biology is just a part of the story
For some people, using GLP-1-mimicking drugs like Ozempic will likely be validating and empowering. They will feel like their biology has been “normalised” in the identical way that blood pressure or cholesterol medication can return people to the “normal” range of measures.
But biologically, obesity isn’t solely about GLP-1 activity with many other hormones, physical activity, and even our gut microbes involved.
Overall, obesity is complex and multifaceted. Obesity isn’t just driven by personal biology and alternative; it has social, cultural, political, environmental and economic determinants.
A weight-centred approach misses the remainder of the story
The weight-centred approach suggests that leading with thinness means health will follow. But changing appetite is just a part of the story in terms of health.
Obesity often co-exists with malnutrition. We attempt to separate the results in research using statistics, but specializing in the advantages of weight-loss drugs without addressing the underlying malnutrition means we aren’t prone to see the improved health outcomes in everyone who loses weight.
Obesity isn’t a problem detached from people
Even when it’s well-intentioned, the rhetoric across the joy of “ending the obesity epidemic” can harm people. Obesity doesn’t occur in isolation. It is people who find themselves obese. And the celebration and hype of those weight-loss drugs can reinforce harmful fat stigma.
Zoran Zeremski/Shutterstock
The framing of those drugs as a “cure” exacerbates the binary view of thin versus fat, and healthy versus unhealthy. These usually are not binary outcomes which might be good or bad. Weight and health exist on a spectrum.
Ironically, while fat persons are told they should shed weight for his or her health, also they are shamed for “cheating” or taking shortcuts by utilizing medication.
Drugs are tools, not silver bullets
The creation of those drugs is a start, but they continue to be expensive, and the hype has been followed by shortages. Ultimately, complex challenges aren’t addressed with easy solutions. This is especially true when persons are involved, and much more so when there isn’t even an agreement on what the challenge is.
Many organisations and individuals see obesity is a disease and imagine this framing helps people to hunt treatment.
Others think it’s unnecessary to connect medical labels to body types and argue it confuses risk aspects (things which might be linked to increased risk of illness) with illness itself.
Regardless, two things will at all times remain true. Drugs can only ever be tools, and people tools should be applied in a context. To use these tools ethically, we’d like to stay mindful of who this application harms along the way in which.
